Last €29.60 EUR
Change Today -0.80 / -2.65%
Volume 104.5K
GRF/P On Other Exchanges
Symbol
Exchange
OTC US
OTC US
NASDAQ GS
OTC US
Continuous
Continuous
Frankfurt
Frankfurt
Mexico
As of 11:38 AM 02/27/15 All times are local (Market data is delayed by at least 15 minutes).

grifols sa - b (GRF/P) Snapshot

Open
€30.90
Previous Close
€30.41
Day High
€30.90
Day Low
€29.36
52 Week High
06/9/14 - €34.60
52 Week Low
10/16/14 - €22.61
Market Cap
11.6B
Average Volume 10 Days
62.6K
EPS TTM
--
Shares Outstanding
130.7M
EX-Date
12/4/14
P/E TM
--
Dividend
€0.25
Dividend Yield
1.56%
Current Stock Chart for GRIFOLS SA - B (GRF/P)

Related News

No related news articles were found.

grifols sa - b (GRF/P) Related Businessweek News

No Related Businessweek News Found

grifols sa - b (GRF/P) Details

Grifols, S.A., a specialty biopharmaceutical company, develops, manufactures, and distributes a range of plasma derivative products primarily in the European Union, Spain, the United States, Canada, and internationally. It specializes in providing infusion solutions, nutrition products, medical devices, and diagnostic instrumentation and reagents for use in hospitals and clinics. The company operates through four divisions: Bioscience, Diagnostic, Hospital, and Raw Materials and Others. The Bioscience division manufactures and sells plasma derivatives for therapeutic use, such as the reception, analysis, quarantine, classification, fractionation, and purification of plasma; and sells and distributes end products. This division offers plasma products, such as IVIG, Factor VIII, A1PI, and albumin; and intramuscular immunoglobulins, ATIII, Factor IX, and plasma thromboplastin components. The Diagnostic division focuses on researching, developing, manufacturing, and marketing in vitro diagnostics products comprising analytical instruments and reagents for diagnostics, as well as blood bank products. This division primarily serves blood donation centers, clinical analysis laboratories, and hospital immunohematology services. The Hospital division manufactures and installs products used by and in hospitals, including parenteral solutions, and enteral and parenteral nutritional fluids. The Raw Materials and Others division is involved in the sale of intermediate pastes and plasma products, as well as provision of engineering services to external companies. The company’s products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and a range of other medical conditions. Grifols, S.A. was founded in 1940 and is headquartered in Barcelona, Spain.

Founded in 1940

grifols sa - b (GRF/P) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

grifols sa - b (GRF/P) Key Developments

Grifols, S.A. Announces Audited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014; Provides Capital Expenditure Guidance for the Period 2014 to 2016

Grifols, S.A. announced audited consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, net revenue of EUR 917.3 million against EUR 695.2 million a year ago. For the year, the company reported net revenues of EUR 3,355,384,000 against EUR 2,741,732,000 a year ago. Operating profit was EUR 857,689,000 against EUR 736,120,000 a year ago. Profit before income tax from continuing operations was EUR 589,680,000 against EUR 497,536,000 a year ago. Profit after income tax from continuing operations was EUR 467,083,000 against EUR 342,054,000 a year ago. Profit attributable to company was EUR 470,253,000 against EUR 345,551,000 a year ago. Net cash from operating activities was EUR 978,928,000 against EUR 592,011,000 a year ago. Diluted earnings per share were EUR 1.37 against EUR 1.01 a year ago. In 2014, the company completed its 2014 CAPEX plan allocating a total of EUR 251.8 million EUR 151.687 million a year ago, to expanding manufacturing facilities both in Spain and the United States, including measures designed to strengthen the Diagnostic division following the expansion of the group’s presence in the trans fusional diagnostics sector, and those aimed at the Hospital division. Adjusted EBITDA was EUR 1,074,159,000 against EUR 917,366,000 a year ago. EBITDA was EUR 1,047,161,000 against EUR 864,588,000 a year ago. Net debt was EUR 3,235.7 million. Adjusted net profit was EUR 597.9 million against EUR 450 million a year ago. The company expects capital expenditure of EUR 6000 million for the period 2014 to 2016.

Grifols, S.A., Board Meeting, Feb 20, 2015

Grifols, S.A., Board Meeting, Feb 20, 2015. Agenda: To consider audited consolidated earnings results for the full year ended December 31, 2014.

Grifols, S.A. to Report Fiscal Year 2014 Results on Feb 26, 2015

Grifols, S.A. announced that they will report fiscal year 2014 results on Feb 26, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GRF/P:SM €29.60 EUR -0.80

GRF/P Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Endo International PLC $85.60 USD +0.36
Hikma Pharmaceuticals PLC 2,473 GBp -96.00
Hospira Inc $87.54 USD 0.00
STADA Arzneimittel AG €28.88 EUR -0.373
UCB SA €68.35 EUR -1.26
View Industry Companies
 

Industry Analysis

GRF/P

Industry Average

Valuation GRF/P Industry Range
Price/Earnings 26.9x
Price/Sales 3.6x
Price/Book 4.4x
Price/Cash Flow 16.6x
TEV/Sales 0.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GRIFOLS SA - B, please visit www.grifols.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.